| Assessment Status | Rapid Review Complete |
| HTA ID | 24030 |
| Drug | Pegylated Liposomal irinotecan |
| Brand | Onivyde® |
| Indication | Liposomal irinotecan in combination with oxaliplatin, 5 fluorouracil (5 FU) and leucovorin (LV) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. |
| Assessment Process | |
| Rapid review commissioned | 24/07/2024 |
| Rapid review completed | 22/08/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pegylated liposomal irinotecan compared with the current standard of care. |
| Full HTA commissioned by the HSE | 02/09/2024 |
The company has not submitted a HTA dossier to the NCPE, therefore the cost effectiveness of the technology could not be proven.